Read this company snapshot
Daily valuation snapshot
TransCode Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.86
- Market capitalization (USD)
- $1,881,566.7
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.01
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RNAZ in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RNAZ in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing RNAZ with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.86 |
| Market capitalization (USD) | $1,881,566.7 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.01 |
No matching rows. Clear the filter to see all records.
Read RNAZ's valuation metrics
Company size
TransCode Therapeutics, Inc. Common Stock's recorded market capitalization is $1,881,566.7. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
RNAZ's recorded price-to-book ratio is 0.01. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research TransCode Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about RNAZ. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow RNAZ's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.